Headline: Sernova (SNA) secures FDA Orphan Drug for Cell Pouch in T3c diabetes prevention

Sernova Corp. (SNA) announced on June 17, 2026, it received U.S. FDA Orphan Drug Designation for its Cell Pouch System. This designation is for autologous islet transplantation (AIT) to prevent insulin-dependent diabetes following total pancreatectomy in patients with Type 3c diabetes (T3c). The status provides significant regulatory and financial incentives, including seven years of market exclusivity post-approval. The Orphan Drug status offers benefits such as tax credits for clinical research, R&D grants, and waiver of user fees. Type 3c diabetes accounts for 5-10% of all diagnosed diabetes cases, often necessitating total pancreatectomy. This procedure typically results in immediate insulin-dependent diabetes. Sernova's AIT, delivered via its proprietary Cell Pouch, aims to preserve the patient's own islet cell function by transplanting them to an immunologically protected environment. The company is currently conducting a Phase 1/2 clinical trial for this specific indication.